Podcasts about Formulary

How One Leader Came Out of Retirement to Transform Home Healthcare Jasper Freeman, Director of National Accounts at SC Pharmaceuticals, didn't just return to medical sales—he came back with a mission to change it. In this episode, Jasper shares how he helped launch Ferosix, a revolutionary heart failure treatment designed to keep patients out of the hospital and improve care at home. But that's just the beginning. We dive into: The untold story of Pharmacy Benefit Managers (PBMs) and their massive influence over drug pricing and access Why the insurance-sales-patient triangle is the key battleground in healthcare innovation What the U.S. can learn from other countries about lowering costs and improving care Bold reform ideas—from slashing med school tuition to rethinking drug distribution This is a rare, behind-the-scenes look at the business of healthcare, guided by someone who's lived it at the highest levels. If you're in medical sales—or trying to break in—this episode is a masterclass on what's next and how to lead the change. Connect with Jasper: LinkedIn Connect with Me: LinkedIn Love the show? Subscribe, rate, review, and share! Here's How » Want to connect with past guests and access exclusive Q&As? Join our EYS Skool Community today!

You have to do the legwork. Nobody will do it for you.Link to full podcast:https://creators.spotify.com/pod/show/dennis3211/episodes/Prolonged-Field-Care-Podcast-Adding-Meds-to-the-Formulary-e306curThank you to Delta Development Team for in part, sponsoring this podcast.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠deltadevteam.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠For more content go to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.prolongedfieldcare.org⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Consider supporting us: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠patreon.com/ProlongedFieldCareCollective⁠⁠⁠⁠⁠⁠⁠⁠⁠ or ⁠⁠⁠⁠⁠⁠⁠⁠⁠www.lobocoffeeco.com/product-page/prolonged-field-care⁠

In this episode of the PFC Podcast, Dennis and Jamie discuss the challenges faced by medics in adding new drugs to their formulary. They explore the roles of medics and doctors, the importance of training and experience, and how to effectively communicate the need for new medications. The conversation emphasizes the need for trust and collaboration between medics and doctors, as well as the importance of understanding local drug availability in future operational environments.TakeawaysThe requirement for new drugs must be justified by a clear capability gap.Medics should master the basics before seeking new medications.Safety and operational appropriateness of drugs are critical considerations.Experience with a drug is essential for medics to advocate for its use.Building trust with doctors is crucial for medics to gain support for new drugs.Training and experience are necessary to prove competency with new medications.Communication is key in discussing drug needs with providers.Medics should use stories and data to support their requests for more medication.Understanding local pharmacology is important for future missions.A full pace plan should include locally available agents. Chapters00:00 Introduction to the Podcast and Guest01:04 Understanding the Role of Medics and Doctors03:08 Evaluating New Drugs for Medic Use06:53 Bridging the Gap Between Medics and Doctors11:00 Training and Experience for Medics20:51 The Process of Adding New Drugs24:34 Proving the Need for More Medication28:10 Building Trust and Communication with Providers30:40 Future Considerations for Medic FormularyThank you to Delta Development Team for in part, sponsoring this podcast.⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠deltadevteam.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠For more content go to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.prolongedfieldcare.org⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Consider supporting us: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠patreon.com/ProlongedFieldCareCollective⁠⁠⁠⁠⁠⁠⁠⁠ or ⁠⁠⁠⁠⁠⁠⁠⁠www.lobocoffeeco.com/product-page/prolonged-field-care⁠

Pull up a chair and join the Three Apothecaries around the fire as we wrap up the year with a lively chat featuring friends and colleagues Clare Howard and Jonathan Underhill. Together, we reflect on an exciting and dramatic year in the ever-changing world of healthcare and medicines.From groundbreaking developments like weight-loss drugs and debates around assisted dying to critical issues such as polypharmacy and exploring new career paths, we dive into the stories that shaped 2024—and how they've impacted us personally and professionally.On a lighter note, What does the weight of the British National Formulary reveal about the history of medicines? What drink smells like a pharmacy? And how measuring Prostate Specific Antigen can be fun!For this episode's micro discussion, we travel back 60 years to explore the 1964 classic, "Patient's View of Admission to a London Teaching Hospital." This fascinating study sheds light on how patient experiences have evolved—and in some cases, stayed the same—over the decades. (Read the paper)This year has been one for the record books, with the Three Apothecaries travelling to Bordeaux and performing for a sell-out audience in Cardiff. We're so grateful to our incredible guests and loyal listeners for making it another unforgettable year of stories, conversations, and medicines-related fun.Merry Christmas and Happy New Year!Check out our website www.theauralapothecary.com  for a searchable database of all episodes, blogs and bonus content for your enjoyment and education.To get in touch and interact follow us on Blue Sky @auralapothecary.pharmsky.app , Twitter @auralapothecary or email us at auralapothecarypod@gmail.com . Don't forget to rate us and comment wherever you have got this podcast from. You can listen to the Aural Apothecary playlist here; https://open.spotify.com/playlist/3OsWj4w8sxsvuwR9zMXgn5?si=tiHXrQI7QsGtSQwPyz1KBg You can view the Aural Apothecary Library here;  https://litalist.com/shelf/view-bookcase?publicId=KN6E3O

In this episode of the Astonishing Healthcare podcast, Nisha Bhide, PharmD, joins Justin Venneri in the studio to discuss an integral aspect of pharmacy benefit management (PBM) - the formulary. They explore everything from what a formulary is to how they are created and P&T committees, why and how often they change, the role JUDI® plays in managing a formulary efficiently, and the difference between open and closed formularies.*Nisha also dives into how specialty drugs fit into the equation, utilization management tools like prior authorization (PA), the role of formularies in helping manage low-cost generic or high-cost brand lists, and more!Related ContentPharmacy Benefits 101: What is a Formulary?Replay - Cracking the Code: Unraveling Specialty Drug Costs & PBM ProfitsCapital Rx Receives a US Utility Patent Covering its Enterprise Health Platform - JUDI®AH035 - Pharmacy Benefits 101: Clinical Programs, with Bonnie Hui-Callahan, PharmDFor more information about Capital Rx and this episode, please visit Capital Rx Insights.*If you'd like to dive into the details of a formulary, check out Capital Rx's Freedom (Open) Formulary Lookup or Capital Rx's Liberty (Closed) Formulary.

In this unsponsored episode, Yafa Sakkejha, CEO of Beneplan, has a conversation with Mitch Hanlon, Vice President of Business Development at Claimsecure, to learn about their custom and unique Formulary Protect management program - plus how he started his own business, how he sold to business owners, and where he sees the industry going.

In this episode of the Astonishing Healthcare podcast, Jillian Lonson, PMP®, Sr. Director, Benefits Administration & Operations, and Jean Beman, Manager, Benefits Operations & Administration, join host Justin Venneri for part one of a two-part discussion about what pharmacy benefit management (PBM) entails. They describe the basics and then peel back the layers of what PBMs do to ensure that a prescription processes correctly - per your pharmacy benefit - so you can pay the correct amount at the pharmacy counter or receive your medication in the mail.Jillian and Jean also share their professional journeys within the PBM industry, highlighting how their roles and teams are central to configuring and testing plan benefits so that formularies, the network, and clinical programs are set up correctly. This informative episode sets the table for a deeper dive into the configuration and testing that go on behind the scenes!Related Content:AH001 - Building a PBM: Tech, Navigating Growth, and Delivering Value with AJ LoiaconoWhat Is the Role of a Pharmacy Benefits Manager (PBM)?Pharmacy Benefits 101: What is a Formulary?Please visit Capital Rx Insights for more information, including this episode's transcript!

This podcast aims to explore what health disparity and equity is, examine their connection to Pharmacoequity and discuss how the P&T committee can address these issues within the formulary review process.  The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.  

In this episode of the Astonishing Healthcare podcast, we tackle one of the more polarizing issues in healthcare: prior authorization (PA for short). Sara Izadi, PharmD, Capital Rx's Chief Clinical Officer, Lorece Shaw, PharmD (Director of PA), and Product Manager Callie Burton-Callegari, join host Justin Venneri for a candid discussion about PA. They cover everything from basics like what a PA is, who decides the criteria, and common reasons for denials to why they are necessary and how technology - AI & ML - can help improve PA workflows.Last but not least, the team shares the most astonishing things they've seen around PAs, including a personal story!For related content, check out:Pharmacy Benefits 101: What is a Formulary?Are Your Prior Authorizations Actually Working?Capital Rx's JUDI® Redefines the Role Tech Plays in the Administration of Medicare, Medicaid, and Commercial Pharmacy Programs (highlighting our new PAT)For this episode's transcript and much more, please visit Capital Rx Insights.Thank you for listening!

This week on the pod, the Aunties debrief about their IRL hang – with white husbands in tow – in Santa Barbara. They spill some serious tea, including the time they both got dumped by the husbands in question (when they weren't yet husbands). Then, they're joined by Liam Gareau, host of the pop culture podcast “Tell Me Everything.” It's unhinged shower routines part 3, as Liam walks us through how he uses his $12 bar of soap and growing Aesop collection.  Need skincare recs, boyfriend advice, or anything in between? Ask the Aunties anything! Drop us a message on Speakpipe. Subscribe to the Add to Cart newsletter for juicy extras. Please note, Add To Cart contains mature themes and may not be appropriate for all listeners.  To see all products mentioned in this episode, head to @addtocartpod on Instagram. To purchase any of the products, see below.  Ku wore these gorgeous Franco Sarto boots in Santa Barbara  Ku and Liam are adding to queue the series “One Day” Liam's $12 Formulary 55 soap bar in Aloe Leaf & Mint is the star of the show  Once he opens up his pores, it's time for a dab of Aesop's Primrose Facial Hydrating  Then he spritzes Aesop's Eeaux de Parfum  Love Liam? Check out Tell Me Everything Stay up to date with us on Twitter, Facebook, and Instagram at @LemonadaMedia.  Joining Lemonada Premium is a great way to support our show and get bonus content. Subscribe today at bit.ly/lemonadapremium.  Click this link for a list of current sponsors and discount codes for this show and all Lemonada shows: lemonadamedia.com/sponsorsSee omnystudio.com/listener for privacy information.

RSV infections are not new and have devastating impacts. The recent advent of new prevention strategies has renewed the focus on the disease with a hopeful outlook. For the last 25 years, the only FDA approved product preventing RSV, lower respiratory tract disease, was palivizumab or Synagis, a monoclonal antibody indicated for use in high risk infants children and administered intramuscularly monthly throughout the RSV season. In May, the first ever RSV vaccines were approved, Arexvy and Abrysvo. These two new RSV vaccines were approved for use in adults greater than or equal to 60 years of age. In August this year, one of the RSV vaccines, Abrysvo, also received approval for expanded use for maternal vaccination to prevent RSV lower respiratory tract disease in infants. Nirsevimab or Beyfortus, a new long-acting monoclonal antibody, was approved in July for prevention of RSV lower respiratory tract disease in infants and children. Compared with palivizumab, nirsevimab is indicated for a much broader patient population including recommended use in all infants less than eight months of age, born during or entering their first RSV season. The rollout of nirsevimab has proved challenging due to supply shortages, among other factors. Today we discuss the new RSV prevention strategies, focusing on the pediatric patient population, as well as the recent shortages with nirsevimab. Dr. Deb Bondi, Dr. Nikolai Dahl, as well as Dr. Kyle Hoelting from Vizient join guest host Vizient's John Schoen for today's podcast.   Guest speakers:  Deb Bondi, PharmD, FCCP, BCPS, BCPPS Pediatric Clinical Coordinator, NICU Clinical Pharmacy Specialist, and PGY2 Pediatric Pharmacy Residency Program Director UChicago Medicine, Comer Children's Hospital   Nikolai Dahl, PharmD Utilization and Formulary Program Manager John Muir Health   Kyle Hoelting, PharmD, BCPS Senior Clinical Manager of Drug Shortages and Drug Information Vizient Center for Pharmacy Practice Excellence    Host:  John Schoen, PharmD, BCPS  Senior Clinical Manager of Evidence-Based Medicine and Drug Information Vizient Center for Pharmacy Practice Excellence   Show Notes:  [02:39-04:09] Update on where everything currently stands with the Nirsevimab supply and what led to the shortage [04:10-05:01] Information on whether or not there's going to be additional supply of either the 50 mg or 100 mg syringes later this season [05:02-06:01] Resources related to mitigating this nirsevimab shortages [06:02-10:29] What University of Chicago and John Muir Health are doing with these new RSV vaccines and the new monoclonal antibody, Beyfortus [10:30-13:15] Formulary decisions University of Chicago and John Muir Health make around nirsevimab and palivizumab [13:16-15:24] Organizational preference for the maternal RSV vaccine or nirsevimab [15:25-20:33] Other logistical issues with either nirsevimab or the maternal RSV vaccines, such us scope of practice consideration, stocking of the VFC product in patient education, et cetera [20:34-22:01] Payment of billing issues either University of Chicago or John Muir Health experienced for either nirsevimab or the maternal RSV vaccine [22:02-24:57] Clinical pearls or advice related to these new prevention strategies   Links | Resources: Vizient member RSV resources RSV vaccines in adults side-by-side comparison RSV monoclonal antibodies in pediatrics side-by-side comparison FAQ pediatric RSV prevention strategies Minute Market Insight on nirsevimab shortage Mitigation strategy on nirsevimab shortage   Subscribe Today! Apple Podcasts Amazon Podcasts Google Podcasts Spotify Android RSS Feed

Dr. Robert Popovian, Chief Science Policy Officer for the Global Healthy Living Foundation, discusses the GLHF's recent webinar on formulary exclusions; and a Forbes article outlines how two states are taking action to protect themselves against insurance policies that don't make sense.. Global Healthy Living Foundation Webinar: Impact of Formulary Exclusions on Individual Patients Forbes News Article: New TN & TX Price Transparency Laws Prevent Patients From Getting Ripped Off  

MacKay Jimeson, Executive Director of the Patients Rising Patient Access and Affordability Project, tells us about their newly-released working paper called ”Prescription Drug Formularies Transparency and Reform.”; Ike Brannon, Senior Fellow at the Jack Kemp Foundation, explains why the CBO is looking for more research on obesity; and the FDA is authorizing more AI-enabled medical devices. Patient Access and Affordability Project Webpage: Equitable Access – Examining Discriminatory & Restrictive Practices in Prescription Drug Formularies Congressional Budget Office Webpage: A Call for New Research in the Area of Obesity CATO Institute Webpage: The Costs of the New Weight Loss Hope Could Be Very High STAT News Article: After a lull, the pace of FDA authorization of AI-enabled medical devices is rising  

Hard to believe but insurance companies can change your plan without asking your permission. ANOC is their sneaky way of announcing those changes! Scan the ANOC carefully for: 1) Premium cost changes; 2) Formulary changes and 3) Anything else that looks suspicious. Contact me at: DBJ@MLMMailbag.com (Most severe critic: A++)   Inspired by: "MEDICARE FOR THE LAZY MAN 2023; Simplest & Easiest Guide Ever!" on Amazon.com. Return to leave a short customer review & help future readers. Official website: https://www.MedicareForTheLazyMan.com

August 31: Today on TownHall Reid Stephan, VP and CIO at St. Lukes speaks with Chuck Podesta, Chief Information Officer at Renown Health. How did Chuck take his organization's IT department from 7% of operating expenses down to 4%? Why is it essential for CIOs to evaluate the relevancy and cost-effectiveness of innovation, like AI, against the organization's size and budget? In what ways can managed services be leveraged to achieve both savings and improvements in non-core areas, like nutrition and environmental services? How does focusing on core IT competencies impact other departments or units within a healthcare organization?As healthcare technology professionals, we're in a seismic shift. Artificial Intelligence is not just a buzzword—it's transforming our field and altering how we deliver healthcare. But with these technological advancements come complex challenges and unique opportunities. Are you ready to navigate this new landscape? Join us, September 7th, 1pm ET for an unmissable journey into the future of healthcare. Register Here. - https://thisweekhealth.com/ai-journey-in-healthcare/Subscribe: This Week HealthTwitter: This Week HealthLinkedIn: Week HealthDonate: Alex's Lemonade Stand: Foundation for Childhood Cancer

Your new drug has made it to the insurers' formulary, but will providers actually prescribe it? Pull-through challenges abound; getting physicians to prescribe your drug means training and coordinating field staff. Encouraging pharmacies to stock and recommend your drug. Educating patients. And more. Lastly, there's the challenge of measuring success – what does successful pull-through look like anyway?Jack Timko, Senior Principal, Valuate Health, returns to The IDI to offer his insights. Follow Jack on LinkedIn.Follow Valuate on LinkedIn or visit us at ValuateHealth.com. 

Uptake of biosimilars is lagging in the US, but why? In this episode, Sarah interviews Juliana M. Reed, Executive Director of the Biosimilars Forum, to find out the real barriers to widespread access to biosimilars, and how these problems could be addressed.Julie discusses the role of pharmacy benefit managers (PBMs) and the incentives that keep them from listing most biosimilars on their formularies. She applauds the recent launch of multiple new biosimilars for the blockbuster biologic Humira and explains why this moment is pivotal for the biosimilars industry and the US healthcare system as a whole. Mentioned during this episode:Interview with Dr. Gillian Woollett, VP, Head of Regulatory Strategy and Policy at Samsung Bioepis – Xtalks Life Science Podcast Ep. 110For more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

Host Fred Goldstein invites Ellen Whipple, Co-owner, Scientific Content Solutions and Vice Chair of the AMCP Format for Formulary Submissions Committee to discuss the AMCP Format for Formulary Submission and the upcoming Release 5.00 Find all of our network podcasts on your favorite podcast platforms and be sure to subscribe and like us. Learn more at www.healthcarenowradio.com/listen/

I get pitched different preferred provider networks all the time. It's a distraction from the financial incentives of plan sponsors. Benefits brokers should instead look at formulary management or PLAs (price level agreements)

Tune in for the latest Payer Issues updates.

Enduring CME will expire on 11/17/2024. The presentation is originating from Northeast Georgia Medical Center Gainesville. Objectives: 1. Outline the “formulary approach” to evaluating each new drug through application 2. Compare and contrast newly approved drugs with older agents regarding their pharmacology, pharmacokinetics, efficacy, safety, dosing and cost. 3. Describe any pipeline drugs that may be significant releases in the next few years. Disclosures: No disclosures Accreditation and Designation: The Northeast Georgia Medical Center & Health System, Inc. is accredited by the Medical Association of Georgia to provide continuing medical education for physicians. The Northeast Georgia Medical Center & Health System, Inc. designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s) TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Recommended medications are always being updated in the guidelines, but the formulary does not change nearly as fast. This is the right way to get things changed.

The recently signed gun law, S. 2938: Bipartisan Safer Communities Act, contained a surprise dingleberry postponing a regulation designed to save seniors money on their pharmaceutical drugs by prohibiting kickbacks to an industry few have heard of: Pharmacy Benefit Managers (PBMs). This little-known but extremely powerful industry deserves much of the blame for ever rising prescription drugs costs in the United States. In this episode, Jen gives you the scoop on PBMs and how they make their money at the expense of Americans who are most dependent on medications. Please Support Congressional Dish – Quick Links Contribute monthly or a lump sum via PayPal Support Congressional Dish via Patreon (donations per episode) Send Zelle payments to: Donation@congressionaldish.com Send Venmo payments to: @Jennifer-Briney Send Cash App payments to: $CongressionalDish or Donation@congressionaldish.com Use your bank's online bill pay function to mail contributions to: 5753 Hwy 85 North, Number 4576, Crestview, FL 32536. Please make checks payable to Congressional Dish Thank you for supporting truly independent media! View the shownotes on our website at https://congressionaldish.com/cd255-pharmacy-benefit-managers-pbms We're Not Wrong Berlin Meetup Contact Justin at WereNotWrongPod@gmail.com Background Sources Recommended Congressional Dish Episodes CD134: The EpiPen Hearing US Healthcare Landscape Jessi Jezewska Stevens. Apr 23, 2020. “A Brief History of the Great American Healthcare Scam.” Bookforum. Tanza Loudenback. Mar 7, 2019. “The average cost of healthcare in 21 different countries.” Insider. Chuck Grassley and Ron Wyden. 2019. “Insulin: Examining the Factors Driving the Rising Cost of a Century Old Drug [Staff Report].” U.S. Senate Finance Committee. “Health Insurance Coverage of the Total Population.” Kaiser Family Foundation. Sara R. Collins and David C. Radley. Dec 7, 2018. “The Cost of Employer Insurance Is a Growing Burden for Middle-Income Families.” The Commonwealth Fund. PBMs What are PBMs? JC Scott. Jun 30, 2022. “Drug manufacturers are root cause of high drug costs; PBMs drive costs down.” The Hill. Zach Freed. Jun 22, 2022. “The Pharmacy Benefit Mafia: The Secret Health Care Monopolies Jacking Up Drug Prices and Abusing Patients and Pharmacists.” American Economic Liberties Project. Adam J. Fein. Jun 22, 2021. “The Top Pharmacy Benefit Managers of 2020: Vertical Integration Drives Consolidation (rerun).” Drug Channels. “Flash finding: How drug money from sick people really works.” Nov 11, 2021. 46brooklyn. Adam J. Fein. Feb 3, 2019. “Don't Blame Drug Prices on ‘Big Pharma.'” The Wall Street Journal. How PBMs Make Money “DIR Fees.” National Association of Chain Drug Stores. “How PBMs Make Money: PBM Practices & Profits.” RxSafe. True North Political Solutions. Oct 25, 2017. “White Paper: DIR Fees Simply Explained.” Pharmacy Times. ACA “Vertical Integration” Loophole Peter High. Jul 8, 2019. “A View From Inside Cigna's $67 Billion Acquisition Of Express Scripts.” Forbes. Angelica LaVito. Nov 28, 2018. “CVS creates new health-care giant as $69 billion merger with Aetna officially closes.” CNBC. David Dayen. Oct 12, 2018. “Why the Aetna and CVS Merger Is So Dangerous.” The American Prospect. Jeff Byers. April 12, 2018. “Optum a step ahead in vertical integration frenzy.” Healthcare Dive. Graph: Optum opens up wider market for UnitedHealth Group Graph: Optum's pharmacy business contributes the majority of its revenue Susan Morse. May 10, 2017. “Secret weapon: UnitedHealth's Optum business is laying waste to old notions about how payers make money.” Healthcare Finance. Lobbying “Client Profile: Pharmaceutical Care Management Assn.” Open Secrets. The Demise of Independent Pharmacies Christine Blank. Oct 17, 2019. “Independents Prepare to Close Up Shop.” Drug Topics. Paulina Firozi. Aug 23, 2018. “The Health 202: Here's why rural independent pharmacies are closing their doors.” The Washington Post. What Is a Formulary? Ana Gascon Ivey. May 19, 2020. “A Guide to Medication Formularies.” GoodRx. Previous Delays in Rebate Regulation Paige Minemyer. Jan 29, 2021. “In a win for PBMs, Biden administration delays rebate rule.” Fierce Healthcare. Paige Minemyer. Jan 12, 2021. “PCMA sues Trump administration over rebate rule.” Fierce Healthcare. “Incorporating the Effects of the Proposed Rule on Safe Harbors for Pharmaceutical Rebates in CBO's Budget Projections—Supplemental Material for Updated Budget Projections: 2019 to 2029.” May 2019. Congressional Budget Office. The Gun Law Passage Process Office of the Clerk. May 18, 2022. “Roll Call 212 | Bill Number: S. 2938.” U.S. House of Representatives. Tampa Bay Times Editorial Board. May 12, 2022. “Republican lawmakers should be ashamed for failing to honor Justice Joseph Hatchett.” Miami Herald. Annie Karni. Apr 12, 2022. “House G.O.P., Banding Together, Kills Bid to Honor Pioneering Black Judge.” The New York Times. Background on Most Important Provisions Mary Katherine Wildeman. May 26, 2022. “Data show most school shootings carried out by young adults, teens.” CT Insider. Jeffrey Pierre. May 26, 2022. “Experts say we can prevent school shootings. Here's what the research says.” NPR. The Dingleberry Erik Sherman. Jun 30, 2022. “Gun Safety Bill Extends Drug Middlemen Protection From Anti-Kickback Measure.” Forbes. Molly Rutherford. Jun 28, 2022. “Gun legislation provision puts drug supply chain profits over patients.” The Hill. Marty Schladen. Jun 22, 2022. “Deep inside the gun bill: a break for prescription drug middlemen.” Iowa Capital Dispatch. Poland Train Station Taylor Popielarz, Maureen McManus and Justin Tasolides. Mar 25, 2022. “‘The help given is remarkable': Inside the Poland train station that's become a hub for Ukrainian refugees.” Spectrum News NY1. The Law and the Regulation S. 2938: Bipartisan Safer Communities Act Senate Vote: 65-33 (All Nos GOP) House Vote: 234-193 (All Nos GOP) Jen's Highlighted PDF of S. 2938: Bipartisan Safer Communities Act Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees U.S. Health and Human Services Department November 30, 2020 Audio Sources The State of Competition in the Pharmacy Benefits Manager and Pharmacy Marketplaces November 17, 2015 House Committee on the Judiciary Witnesses: Bradley J. Arthur, R.Ph., Owner, Black Rock Pharmacy David Balto, Law Offices of David A. Balto PLLC Amy Bricker, R.Ph. Vice President of Retail Contracting & Strategy, Express Scripts Natalie A. Pons, Senior Vice President and Assistant General Counsel, CVS Health Clips 53:48 Bradley Arthur: The Big Three PBMs control almost 80% of the entire market and these PBMs have the upper hand both in negotiating the contract with the payer, as well as strongly influencing the actual plan design itself. The PBM industry typically states that they can use their economic power to harness enhanced market efficiencies, but for whom? However, the staggering annual revenues that continue to grow each year of the big three suggests that these efficiencies are going directly to their corporations' bottom lines. Small community pharmacies like mine are faced on a daily basis with the impact of the PBMs' disproportionate market power. Community pharmacies routinely must agree to take-it-or-leave-it contracts from the PBMs just to continue to serve our long-standing patients. As if that weren't enough, the PBMs also directly set the reimbursement rates for pharmacies, the very same pharmacies that stand in direct competition of some of these PBM-owned mail-order and specialty pharmacies. Therefore, it comes as no surprise that the PBMs present employer and government payers with carefully tailored suggested plans designs that steer beneficiaries to these PBM-owned entities. Drug Pricing in America: A Prescription for Change, Part I January 29, 2019 Senate Committee on Finance Witnesses: Kathy Sego, Mother of a Child with Insulin-Dependent Diabetes Douglas Holtz-Eakin, Ph.D., President, American Action Forum Mark E. Miller, Ph.D., Vice President of Health Care, Laura and John Arnold Foundation Peter B. Bach, MD, MAPP, Director, Memorial Sloan Kettering Center for Health Policy and Outcomes Clips 1:57:30 Sen. John Cornyn (R - TX): Can anybody on the panel explain to me why we have a general prohibition against kickbacks — they call them rebates — under the Social Security Act, but we nevertheless allow it for prescription drug pricing? What's the sound public policy reason for excluding prescription drug pricing from the anti-kickback rule under federal law? Douglas Holtz-Eakin: I can't explain that and won't pretend to. [laughter] Sen. Cornyn: I thought I was the only one who didn't understand the wisdom of that. Well, it's not a transparent arrangement and it does produce upward pressure on drug prices. And obviously, the negotiations between the PBM and the pharma in terms of what the net cost is, is not transparent, nor is it delivered to the consumer. Is it Dr. Miller? Dr. Bach? Peter Bach: It's delivered to the consumer indirectly through the reduction of the total cost of the benefit, but it is not delivered to the actual consumer using the drug, and that is a disassociation, that is a problem. Because it essentially reverses the structure of insurance. Lowering the total costs are people who use it the least, and raising the costs are people who use it the most, relative to if you allowed the rebate to be used at the point of sale, including all discounts. 1:59:49 Douglas Holtz-Eakin: If we had the negotiation be about the upfront price, so instead of a high list price and a rebate, you just negotiate a lower price, that would be the price that Ms. Sego would pay and insurance companies would look at that and say, okay, she's not paying as much as she used to, we're going to have to make up that money somewhere else and they might raise premiums. That means that people who don't have extreme insulin drug costs would pay a little bit more in a premium every month, and people who have extremely devastating medical conditions and high health care costs would get less costs. That's exactly what insurance is supposed to do. And so the rebate system is more than giving strange incentives on pricing. It's undercutting the purpose of insurance in general. Drug Pricing in America: A Prescription for Change, Part II February 26, 2019 Senate Committee on Finance Witnesses: Richard A. Gonzalez, Chairman and Chief Executive Officer, AbbVie Inc. Pascal Soriot, Executive Director and Chief Executive Officer, AstraZeneca Giovanni Caforio, M.D., Chairman of the Board and Chief Executive Officer, Bristol-Myers Squibb Co. Jennifer Taubert, Executive Vice President, Worldwide Chairman, Janssen Pharmaceuticals, Johnson & Johnson Kenneth C. Frazier, Chairman and Chief Executive Officer, Merck & Co., Inc. Albert Bourla, DVM, Ph.D., Chief Executive Office, Pfizer Olivier Brandicourt, M.D., Former Chief Executive Officer, Sanofi Clips 1:22:03 Albert Bourla: Adverse incentives that favor higher cost biologics are keeping biosimilars from reaching patients. In many cases, insurance companies declined to include lower cost biosimilars in their formularies because they would risk losing the rebates from covering higher cost medicines. I can't think of a more concerning example of a broken system and we need to do something about it. 1:33:35 Sen. Chuck Grassley (R - IA): So many of you have voiced support for the recent rebate rule proposed by the administration. Should the administration finalized this rule, will you commit to lowering your drug prices? Richard Gonzalez [CEO, AbbVie]: Mr. Chairman, we are supportive of the rule. We'd like to see it in its final form, obviously, to make a final decision, but we are supportive of taking the discount to the patient at the point of sale. Sen Grassley: Okay. AstraZeneca? **Pascal Soriot [CEO, AstraZeneca]**The same for us Senator, I would go one step further: if the rebates were removed from the commercial sector as well, we will definitely reduce our list prices. Sen Grassley: Okay. And Bristol? Giovanni Caforio [CEO, Bristol-Myers Squibb]: We have the same positions. Sen Grassley: Okay. Johnson and Johnson? Jennifer Taubert [EVP, J&J]: Yes, we're supportive, and that definitely would be my goal. We would just need to see the final legislation, provided that there aren't additional fees that are added into the system to compensate for the rebates. Sen Grassley: Merck? **Kenneth C. Frazier: I would expect that our prices would go down if we change the system. Again, on the commercial side as well as the Medicare side. Sen Grassley: Okay, Pfizer? Albert Bourla [CEO, Pfizer]: It is a very clear intention that we will not keep a single dollar from these rebates. We will try to move every single penny to the patients and we think if this goes also to the commercial plants that will be even better for more patients. Sen Grassley: Okay. Sanofi? Olivier Brandicourt [Former CEO, Sanofi]: Lowering list price has to be linked to better access and affordability at the counter for the patients. 1:35:20 Sen. Ron Wyden (D - OR): Is it correct that your company, and nobody else, sets the starting price for all drugs sold by Pfizer? Yes or no? Albert Bourla: It is a negotiation with PBMs and they are very powerful. Sen. Wyden: But you still get to set the list price? Albert Bourla: Yes, but we set this price and the rebate limit(?). 1:35:40 Sen. Ron Wyden (D - OR): Is it correct, when a hypothetical patient, let's call her Mrs. Jones, goes to pay for her drug at the pharmacy counter, her coinsurance is based on the price of the drug you set? Albert Bourla: It is correct in many cases. Sen. Wyden: Okay. I just want you all to know that the number one reason consumers are getting hammered, is because these list prices, which you have the last word with respect to where they are, are unaffordable. And the high prices are tied to what the consumer pays at the pharmacy counter. And all this other stuff you talk about, the rebates and the discounts and the coupons, all this other stuff is window dressing, all of that. And the fact is on Part D, 40% of the drugs don't even have a rebate. So I want it understood, particularly because I've asked you, Mr. Borla, I think you and others in the industry are stonewalling on the key issue, which is actually lowering list prices. And reducing those list prices are the easiest way for American consumers to pay less at the pharmacy counter. 2:12:45 Sen. Thomas Carper (D-DE): First is eliminating rebates to PBMs. That's the first one, eliminating rebates to PBMs. The second is value based arrangements. And the third is increasing transparency industry-wide on how you set your prices. 2:13:20 Richard Gonzalez: We clearly support providing the discount at the patient level, eliminating rebates essentially. 2:14:10 Pascal Soriot: If the rebates, as I said earlier, were to be removed from Part D and the commercial sector, we would actually reduce our list prices. 2:15:10 Giovanni Caforio: I would say that not only do we support all three elements that you mentioned, but I do believe those three elements together with the continued effort to develop a generic and biosimilar market would mean significant change, and would clearly alleviate the concerns that patients have today. 2:14:44 Jennifer Taubert: We are very supportive of all three elements that you outlined 2:15:52 Kenneth Frazier: We too support all three. 2:15:55 Albert Bourla: All three elements are transformational for our industry, will disrupt it. However, we do agree that these are the three things that need to be done and also I believe that will have significant meaningful results if we do. 2:16:10 Olivier Brandicourt: We support the three Senator, but we want to keep in mind at the end of the chain the patient has to benefit, so if rebates are removed it has to be to the benefit of patients. Sen. Thomas Carper (D-DE): Good, thanks. 2:18:10 Albert Bourla: 50% of the American people are in commercial plans and these rebate rules apply to Medicare. If the rules apply to all, definitely the list price will go down. 2:18:30 Albert Bourla: The list price is not irrelevant, it's very relevant for a lot of people because they have to pay list price during the deductible period. However if the rebate rule is applied, then they become irrelevant because the patients will not be paying the list price at the purchase point. 2:19:10 Sen. John Thune (R-SD): How would manufacturers respond if the rebate rule were finalized for government programs? I mean, what does that what does that mean for the commercial market? Albert Bourla: Senator, as I said before, all these proposals that they're discussing, [undistinguishable], eliminating the rebate rule, are transformational and will disrupt the way we do business. I don't know exactly how the system will evolve, and I really don't favor a bifurcated system. I would like to have a transparent single system across both parts. So we need to see how the whole thing will evolve. 2:25:26 Johnny Isakson (R-GA): Who sets the discount and who sets the rebate? 2:26:20 Richard Gonzalez: We negotiate with payers, so managed care and PBMs— Sen. Johnny Isakson (R-GA): You're a supplier though, so you have to go negotiate with the PBMs and those people, is that right? Richard Gonzalez: Correct, and they negotiate aggressively. Sen. Isakson: Is that pretty much true with everybody, that they're the major component between the end retail consumer price and the origin of the product? Richard Gonzalez: Yes, Senator. Sen. Isakson: Well, that seems like that's someplace we ought to focus, because that's where the distorted numbers come in. Johnson & Johnson, Janssen, in your testimony, you talked about your average list price of 8.1%, up, but an average net price change of only 4.6%. So while your gross went up 8.6, your net went down 4.6 In the same pricing period. How does that happen? If you're setting the price, how does it not go up on the bottom? Jennifer Taubert: Yeah, and in fact, in 2018, our net price actually declined 8.6%, so even more than that. The intermediaries in the system are very, very effective negotiators— Sen. Isakson: Tell me who the intermediaries are. Jennifer Taubert: Those would be the PBMs and the insurers. Sen. Isakson: …and the insurance companies? Jennifer Taubert: Right, and they set the formularies for patients. Sen. Isakson: And they're not the same. They're two different people? Jennifer Taubert: Yes, correct. 2:40:45 James Lankford (R-OK): All of you have mentioned the rebate issue has been a problem and that insurance companies and PBMs are very effective negotiators. Part of the challenge of this is, health insurance companies pay their PBM based on the quality of their negotiation skills, cutting a price off the list price. And so if a list price is higher and a rebate is higher, that also gives preference to them. So the difficulty is, as you raise list price, and the rebate gets larger, the insurance company gives that preference, making it harder for biosimilars. Am I tracking this correctly? 2:43:00 Albert Bourla: Here in the US, the penetration of biosimilars is much lower than in other places, but it is disproportional to different parts of the US healthcare system. For example, in open systems, systems where the decision maker it is a PBM, the one biosimilar we have has a market share of 5% in the US. In closed systems, in systems like Kaiser, for example, integrated healthcare systems where the one who decides has the whole cost of the healthcare system in its interest, we have 73%. 5% and 73% for the same product. I agree with what Mr. Fraser said that we need to create incentives, but I would add also that we need to break this rebate trap that creates significant disincentives for providers, and the healthcare system, and insurance companies. 3:19:25 Kenneth Frazier: If you went back a few years ago, when we negotiated to get our drugs on formulary, our goal was to have the lowest copay by patients. Today the goal is to pay into the supply chain the biggest rebate, and so that actually puts the patient at a disadvantage since they're the only ones that are paying a portion of the list price. The list price is actually working against the patient. 3:19:50 Sen. Steve Daines (R-MT): Why do we have a system today? Where you all are setting, I'll just say very, very high list prices, which is the starting point for negotiation. Why? Olivier Brandicourt: Senator, we're trying to get formulary position. With those list prices. High list price, high rebates. It's a preferred position. Unfortunately the preferred position doesn't automatically ensure affordability at the end. Kenneth C. Frazier: Senator, If you bring a product to the market with a low list price in this system, you get punished financially and you get no uptake because everyone in the supply chain makes money as a result of a higher list price. Drug Pricing in America: A Prescription for Change, Part III April 9, 2019 Senate Committee on Finance Witnesses: Steve Miller, MD, Former Executive Vice President and Chief Clinical Officer, Cigna Corporation Derica Rice, Former Executive Vice President and President, CVS Health and CVS Caremark William Fleming, Pharm.D., Segment President, Healthcare Services, Humana Inc. John Prince, Chief Executive Officer, OptumRx Mike Kolar, JD, Interim President & CEO, Senior Vice President and General Counsel, Prime Therapeutics LLC Clips Sen. Ron Wyden (D - OR): Pharmaceutical Benefit Managers first showed up decades ago, back when prescription drugs were being utilized more extensively. The PBMs told the insurance companies, “we're the ones who know drug pricing, we will handle the negotiations for you.” But there is little evidence that the pharmaceutical benefit managers have actually held down the prices in a meaningful way. In fact, most of the evidence shows just the opposite. Pharmaceutical Benefit Managers actually make more money when they pick a higher price drug over a lower price drug. Colleagues, let's remember that all the way through this discussion, benefit managers make more money when they pick a higher price drug over a lower price drug. The logic on this isn't exactly complicated, graduate-level economics. PBM profits are based on taking their slice of the prescription-drug pie. More expensive drugs means there's a bigger pie. When there's a bigger pie, [there are] bigger slices for the pharmaceutical benefit managers. 50:24 Mike Kolar: Rebates and the role they play have been key areas of focus in the drug cost debate. In our view, rebates are a powerful tool to offset high prices, which are set by pharmaceutical companies, and pharmaceutical companies alone. The fact that rebates are not offered on many of the highest cost drugs, and that studies show no correlation between prices and rebates underscore that rebates are a key to mitigating rather than causing high drug prices. We pass rebates through fully to our plans, and we believe our plans should be able to choose how to apply these rebates in ways that best serve their members and market needs by balancing premiums and cost sharing. 56:05 Sen. Chuck Grassley (R-IA): I'd like to talk about consolidation, including the recent integration of PBMs with insurance companies. Last year I wrote to the Justice Department on the issues, it reported that the three largest PBMs who are before us today now covers 71% of Medicaid, Medicare Part D enrollees and 86% of standalone Drug Plan enrollees. 57:45 Derica Rice: This is a highly competitive space. In addition to the three that you've pointed out here, CMS has noted there are over 60 PBMs across the US. Therefore, the competition, there's many options for the employers that are out there, government entities, as well as unions to choose from given their specific needs. 1:10:35 Sen. Debbie Stabenow (D-MI): So when we look at Express Scripts has 100 million Americans covered, CVS 90 million, OptumRx 65 million, Prime Therapeutics 27 million, Humana 21 million, and yet Americans still pay the highest prices in the world. Even though you are negotiating for millions of people. The VA has its own pharmacy benefit manager service, they negotiate for 9 million veterans, and they pay, on average, 40% less for the same drugs that the rest of the healthcare system pays for. Despite greater volume, you are unable to secure these kinds of low prices. With all due respect, you guys are pretty bad negotiators. Given the fact that the VA can get 40% less. And so I'd like to know from each of you why that's the case. Dr. Miller? Steve Miller [Former EVP and Chief Clinical Officer, Cigna Corporation]: Yes. Part of the equation is giving patients choice. At the VA, they actually limit their formulary more than any of us at this table do. So oftentimes, they'll have one beta blocker, one ace inhibitor. And so if it's going to get to that level of choice, then we could get better prices also. Sen. Stabenow: Let me jump in, in the interest of time. I know you create nationwide drug formularies, you have pre-authorization, you give preferred status to certain medications. So you don't use any of those tools that the VA is using? Because you do. Steve Miller: We definitely use those tools, but we also give people choice. It's crucial for both physicians and patients to have the choice of the products they want to be able to access. Many of our plans want us to have broad formularies and when you have more products, it means you move less market share. Sen. Stabenow: So basically you're saying a 40% premium gives them more choice. 1:24:30 Sherrod Brown (D-OH): If the administration's rebate rule were finalized as proposed, would you in some way be required to change the way you do business? Mike Kolar: Yes, Senator we would. John Prince: Yes. William Fleming: Yes. Derica Rice: Yes. Steve Miller: Yes. Sen. Brown: Thank you. 1:25:05 Sherrod Brown (D-OH): What percentage of prescriptions that you fill across Part D actually receive a rebate? Roughly what percentage? Mike Kolar: So Senator, approximately 8% of the prescriptions that we cover in Part D are associated with a rebate. Sen. Brown: Okay, Mr. Prince? John Prince: Senator, I don't know the exact number, I know our overall business is about 7%. Sen. Brown: Okay, thank you. William Fleming: About 7-8%. Derica Rice: Senator, I do not know the exact number but we pass through 100% of all rebates and discounts. Sen. Brown: [Grunt] Steve Miller: 90% of the prescriptions will be generic. Of the 10% that are branded, about two-thirds have rebates. So it's about seven-- Sen. Brown: 7-8% like the others. Okay. To recap, PBMs do not set drug prices. Forcing you to change the way you do business -- as the administration's rule would — will not change that fact. And while the rule might impact a small percentage of drugs and Part D that receive a rebate, it does nothing to lower costs, as your answer suggests, for the other 90% of prescriptions you fill. Most importantly, absolutely nothing in the proposed rule would require Secretary Azar's former employer or any other pharma company to lower the price of insulin or any other drug. It's important to establish that, so thank you for that. 1:41:40 Catherine Cortez Masto (D-NV): Let me ask you, Dr. Fleming, in your testimony, you say Humana's analysis of the rebate rule -- and we're talking about the administration's rebate rule now — found that approximately 17% of beneficiaries will see savings at the pharmacy counter as a result of this rule. Can you tell me a little bit more about who these people are? And what kind of conditions do they have? William Fleming: Senator, there will be a number of members who are taking brand drugs for which we get rebates and so it could vary all the way from the common chronic conditions, things like diabetes or hypertension or high cholesterol, all the way over to occasionally, not usually, but occasionally on the specialty drug side. When you think of some medications like treatments for rheumatoid arthritis, multiple sclerosis, places where there's competition. Cover Art Design by Only Child Imaginations Music Presented in This Episode Intro & Exit: Tired of Being Lied To by David Ippolito (found on Music Alley by mevio)

Otsuka Pharmaceuticals is expanding its mental health formulary – looking beyond traditional medications to psychedelics, and to the “intersection of technology and psychiatry” with digital therapeutics currently in clinical trials for Major Depressive Disorder. Kabir Nath, Senior Managing Director of Otsuka's Global Pharmaceutical Business, lets us in on the thinking behind these bold moves, why the pharma co is even innovating to expand the spectrum of treatments available for mental illness in the first place, and how soon these new therapies will reach patients. “Follow the science” is a key undercurrent of this conversation, particularly as we talk through Otsuka's investments in psychedelic medicine start-ups Compass Pathways and, more recently, Mindset. Kabir says the body of clinical evidence for these therapies is building and we get his prediction on when they might become more mainstream and readily available. We also get his take on digital therapeutics (DTx) and the work Otsuka is doing with Click Therapeutics in Major Depressive Disorder. Their clinical trial, done in partnership with Verily, is the first-ever fully remote clinical trial conducted in this space, and the hope is that it not only generates evidence to support the emerging DTx category, but that it also sets a precedent for a new, tech-enabled way to run clinical trials. This is just the beginning. There's lots more on the innovations changing pharma and the future of mental health care in this one. Watch now! Jessica DaMassa, the emerging ‘It girl' of health tech interviewing, chats it up with the ‘who's who' of the health tech and healthcare innovation set on 'WTF Health - What's the Future, Health?' Catch 100's of interviews with leading health tech startups and the VC investors, health insurance companies, big pharma co's, and hospital systems helping bring their new ideas into the healthcare establishment. From AI and Big Data to digital health, virtual care, telehealth, digital therapeutics, payment model innovation, and investing, Jessica helps you spot the trends and figure out what's next.

On this episode, we are joined by Dr. Nina Lathia, BScPhm, RPh, MSc, PhD, to discuss the process of developing and managing a drug formulary. Dr. Lathia is a pharmacist and health economist in Toronto, Canada. She defines a drug formulary and explains some of the criteria used to establish a specific formulary. She also reviews some of the following:  - Comparative effectiveness studies including clinical trials, and real-world studies including a discussion of pros and cons of RCTs vs. real-world studies - Using the PICO (population, intervention, comparator, outcomes) framework to evaluate studies; - Types of studies that best inform safety outcomes (adverse events) - Economic studies – a brief overview of cost-effectiveness analysis - Principles of fair access to prescription drugs - Challenges that prescribers and clinicians experience when trying to navigate formularies You can contact Dr. Lathia at the following e-mail address or at her LinkedIn profile: nina.lathia@healthcaredecisionmaking.com LI profile: https://www.linkedin.com/in/ninalathia/   If you want some handouts on study design from Dr. Lathia, click the link below: Study Design Review   Thanks for listening! If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. You can find our account at the website below:  www.patreon.com/corconsultrx If you have any questions for Cole or me, reach out to us on any of the following: Text - 415-943-6116 Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com Instagram and other social media platforms - @corconsultrx This podcast reviews current evidence-based medicine and pharmacy treatment options. This podcast is intended to be used for educational purposes only and is intended for healthcare professionals and students. This podcast is not for patients and not intended as advice or treatment.

In this episode, Dr. Christopher Tookey and Dr. Rose Wolbrink discuss what is meant by saying a medication is "on formulary" as well as some other common terms. Knowing this can help cut down on expense when it comes to filling medications.   A disclaimer, we're providing general guidance but everyone is different and you should always discuss with your health care professional management of any disease and therapy before trying anything you discover from a source on the internet (including this podcast). This podcast does not reflect the opinion of our employer. 

From Andi Lynn's "About Me" Page. You've probably heard “you are what you eat.” At Andi Lynn's, we make the highest quality herbal remedies that are steeped in tradition and backed by science. We source premium, organic, whole plant ingredients, from global farmer co-ops and blend them by hand in small batches in our FDA kitchen in the USA. Our remedies are high potency and third party tested. Since 2011, I've been dedicated to perfecting these formulas to create products that improve the wellness opportunities for families all across the globe by providing targeted and effective herbal solutions. Join me in bridging western and complementary botanical remedies as we normalize the use of plants as medicine! xo, Andrea Leyerle, CEO Andi Lynn's Pure & Custom Formulary. Andi Lynn sits down with Local Leaders the Podcast host Jim Chapman and they discuss not only the many benefits of "the berry" but also learn about the history of this amazing business that was born and bred in Livingston Parish, Louisiana. You won't want to miss it! #AndiLynn #Elderberry #Podcast #LocalBusiness #Livingstonparish Andi Lynn on the web: https://andilynns.com AMAZON LINKS TO OUR EQUIPMENT Shure SM7B Microphone: https://amzn.to/3cUjIJl RGB LED Video Light, GVM 800D Video Lighting Kit with APP Control: https://amzn.to/3ldBKuN Rode RODECaster Pro Podcast Production Studio: https://amzn.to/3FN8cfg Gator Frameworks Deluxe Desk-Mounted Broadcast Microphone Boom Stand For Podcasts & Recording; Integrated XLR Cable: https://amzn.to/3nVEfDQ Shure SRH440 Professional Studio Headphones designed for Home and Studio Recording, Black: https://amzn.to/3o0a2DK Sony Alpha a6400 Mirrorless Camera: Compact APS-C Interchangeable Lens Digital Camera with Real-Time Eye Auto Focus, 4K Video & Flip Up Touchscreen: https://amzn.to/3E31Zva Sigma 16mm f/1.4 DC DN Contemporary Lens: https://amzn.to/32FImvB Amazon Basics 60-Inch Lightweight Tripod with Bag: https://amzn.to/3CYJPcR LOCAL LEADERS THE PODCAST LINKS: Our Website: www.LocalLeadersThePodcast.com Our Facebook: https://www.facebook.com/LocalLeadersPodcast Our Instagram: https://www.instagram.com/localleaderspodcast/ THANK YOU TO THESE LOCAL BUSINESSES FOR THE SUPPORT! Denham Springs Fit Body Boot Camp: https://getfitdenhamsprings.com/getfitdenhamsprings Sondra Richard Realtor www.SondraSellsHouses.com Green Leaf Charcuterie Boards: https://greenleafcharcuterieboards.com Fit Blendz Denham Springs: https://fitblendz.revelup.com/weborder/?establishment=12 BJ Pawn www.BJPawn.net Blaksheep Creative https://blaksheepcreative.com​​​​ SR Enterprise Painting https://www.facebook.com/SR-Enterprise-848358978571390 HomeKey Mortgage: Tiffany Sicard https://www.facebook.com/TiffanyGuehoSicardMortgageSr.LoanOfficer William Waldrep TWFG https://agentpages.twfg.com/williamwaldrep/ --- Support this podcast: https://anchor.fm/localleadersthepodcast/support

Daj recounts her 2021 weight loss journey and success using Wegovy (available only by prescription). Daree is thinking about using it too! Listen to see why.     @thecmonsonpod thecmonsonpodcast@gmail.com Voicemail: 757-204-5495

As Pharmacists, we're all familiar with Medicaid and Medicare services to an extent. We've processed a claim through them before, have told patients about Open Enrollment, and hear about it quite regularly. However, what's it like being a pharmacist for human services and health care programs. Dr. Fatima Ali is the Senior Pharmacy Director of Medicaid Pharmacy Services at Commonwealth of Kentucky Cabinet for Health and Family Services. She graduated from Philadelphia College of Pharmacy in May 2018 with her PharmD. Since then, Fatima has worked in the managed care setting. She completed a one-year residency at Horizon NJ Health in Pennington, NJ. Horizon NJ Health is the largest Medicaid MCO in New Jersey serving over 800,000 members. Thereafter, Fatima worked for RxAdvance, a small PBM based out of Massachusetts. In August 2020, Fatima joined Kentucky DMS as the Associate Pharmacy Director where she managed the pharmacy benefit for MCO and FFS members.

Please Leave a Review!   This week on A Tale of Two Hygienists TIPisode we are joined by Andrew Johnston, RDH to talk about reviewing products and building out your formulary so that it benefits patients, clinicians and practice owners alike.    Quotes   “It was a great starting point. But it is our responsibility to listen to the clinician's feedback on each of these products and make changes.”   “Sometimes we pay a little more for the name brand unit of something because the clinical experiences or studies on it have been solid for decades.”   “We have GC America in our formulary primarily because they check all the boxes we have.”   Links   http://www.gcamerica.com    Andrew@ATaleofTwoHygienists.com 

Please Leave a Review!   This week on A Tale of Two Hygienists TIPisode we are joined by Andrew Johnston, RDH to talk about reviewing products and building out your formulary so that it benefits patients, clinicians and practice owners alike.    Quotes   “It was a great starting point. But it is our responsibility to listen to the clinician's feedback on each of these products and make changes.”   “Sometimes we pay a little more for the name brand unit of something because the clinical experiences or studies on it have been solid for decades.”   “We have GC America in our formulary primarily because they check all the boxes we have.”   Links   http://www.gcamerica.com    Andrew@ATaleofTwoHygienists.com 

Scott Heisler, Principal Consultant and Innovation Specialist with Kaiser Permanente and Dan Trencher, SVP of Corporate Strategy with Teladoc Health joined hosts Laura Evans and AHIP President Matt Eyles to discuss the digital tools that are available to help patients address their mental health and wellness needs.

Scott Heisler, Principal Consultant and Innovation Specialist with Kaiser Permanente and Dan Trencher, SVP of Corporate Strategy with Teladoc Health joined hosts Laura Evans and AHIP President Matt Ey

The targeted medication safety best practice for hospitals #13, eliminating injectable promethazine from the formulary, will be discussed. Faculty will describe the process used at one health system to address this safety recommendation. Hear tips that you can apply to your practice. The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

With the FDA's  recent approval of a new drug to treat people suffering from Alzheimer's disease, the approval could be a nightmare drug spending scenario -- an extremely expensive product that millions of desperate patients could be eligible for. What factors went into that decision? And what can be done to lower the out-of-pocket cost of prescription drugs for consumers? Matt Vesledahl, a Senior Vice President with  UnitedHealthcare, offers his perspective.

The Wendy Love Edge Show does not dispense medical advice and all of your health choices are your own. Guests: Kari Taylor, Founder of Fractal Health, is a Cannabis Consultant; Formulary; Alchemist; Herbalist; and Certified Detoxification Specialist. She is a committed patient advocate and advisor, with the privilege of empowering people to take charge of their health through holistic and natural medicine solutions. Formulary; Alchemist; Herbalist; and Certified Detoxification Specialist. She is a committed patient advocate and advisor, with the privilege of empowering people to take charge of their health through holistic and natural medicine solutions. Lelehnia Du Bois- Using a lifetime of cannabis experience and well-developed problem-solving skills to help businesses navigate the cannabis industry. Lelehnia has advised in the development of cannabis businesses from seed to retail, developed product lines, launched the Emerald Triangle edition of Sensi Magazine, and serves as a county commissioner. Her extensive experience has helped her clients successfully navigate through the complex challenges a new industry can create. Amanda Rey and The West St Blues Band- Amanda Rey is a Northwest Arkansas based singer/songwriter. Genres: blues, r&b, soul, rock, country Dr Brian Nichol, Cannabis Expert MD cannabisexpertmd.com Dr NIchol is an anethesiologist and cannabinoid physician based in Little Rock, Arkansas Miss Teddi- @learnfromteddi Thanks to our sponsors: 131 Inclusion Gallery Karas Healthcare The Relevnt App Purely Natural CBD Highlands Residential Morgtage Uptown Kitchen and Taphouse Country Doc Walk In And Wellness Lit Premium Smoking Supplies Ozark Authentic KJ's Wellness Join us on Patreon https://patreon.com/thewendyloveedgeshow --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/thewendyloveedgeshow/support

Dr. Brent Moody discusses non-medical switching and formulary exclusions, how they affect both dermatology patients and practices, and what the dermatologist can do to advocate for their patients.

Darci Wingard, Strategic Accounts Manager of the Western Region for Planmeca USA talks about measuring DSO formulary compliance, vendor relationships, budgets, compliance metrics, reporting and much more. Our podcast series brings you dental support and emerging dental group practice analysis, conversation, trends, news and events. Listen to leaders in the DSO and emerging dental group space talk about their challenges, successes, and the future of group dentistry. The Group Dentistry Now Show: The Voice of the DSO Industry has listeners across North & South America, Australia, Europe, and Asia. If you like our show, tell a friend or a colleague.

2020 IS OVER!!! Well, almost anyway. Before we end the weirdest year ever, we wanted to give you one more episode. We discussed a bunch of random stuff like the supreme court and vaccine approvals (YAY!). We also discussed formularies and how they work. Jan 1 is nigh and formulary changes come with it. email: econrxpodcast@gmail.com Twitter/Instagram: @EconRx LinkedIn: www.linkedin.com/company/econrx Website: https://econrx.libsyn.com/

Welcome all to IS PHARMACOLOGY DIFFICULT Podcast! I am Dr Radhika Vijay. Does your textbook cover all the minute details, I mean all, everything like trade names, drug information, purity, chemical, physical characteristics, etc? Well, if not, in today's episode you will get the knowledge of drug information sources, especially official ones.The collective term used for drug literature is "Drug Compendia". When I say its official, it means that government supervises it. The two main Official Drug Compendia are Pharmacopeia and Formulary. Pharmacopoeia is supervised in a country by a set of chosen physicians. It covers drug details like chemical structure and properties, physical properties and molecular weight, assay techniques, drug preservation and storage methods, etc. Such a kind of information is very useful for drug regulators and drug manufacturers. Its hardly of any use to the clinical practitioners. Some well known ones are IP (Indian pharmacopoeia), BP (British pharmacopoeia), USP (United States Pharmacopoeia) Next, I want to talk about Formulary, its supervised in a land by set of pharmacists. Very useful information like drug use indications, drug dose, dosage form, cautions, contraindications, side effects and much more is covered in this. Description of drug class precedes the discussion of drug itself. Some well known examples are British National Formulary (BNF), National Formulary of India (NFI). With this chit chat about Official Drug Compendia, next topic to be discussed is Non Official Drug Compendia, surely to be in next episode...I will be call it for the day, Wishing you all a great , safe weekend!! For all the updates and latest episodes of my podcast, please visit www.ispharmacologydifficult.com where you can also sign up for a free monthly newsletter of mine. It actually contains lot of updates about the medical sciences, drug information and my podcast updates also. You can follow me on different social media handles like twitter, insta, facebook and linkedin. They all are with same name "IS PHARMACOLOGY DIFFICULT". If you are listening for the first time, do follow me here, whatever platform you are consuming this episode, stay tuned, do rate and review on ITunes, Apple podcasts, stay safe, stay happy, stay enlightened, Thank you!!

Welcome all to IS PHARMACOLOGY DIFFICULT Podcast! I am Dr Radhika Vijay. Does your textbook cover all the minute details, I mean all, everything like trade names, drug information, purity, chemical, physical characteristics, etc? Well, if not, in today's episode you will get the knowledge of drug information sources, especially official ones.The collective term used for drug literature is "Drug Compendia". When I say its official, it means that government supervises it. The two main Official Drug Compendia are Pharmacopeia and Formulary. Pharmacopoeia is supervised in a country by a set of chosen physicians. It covers drug details like chemical structure and properties, physical properties and molecular weight, assay techniques, drug preservation and storage methods, etc. Such a kind of information is very useful for drug regulators and drug manufacturers. Its hardly of any use to the clinical practitioners. Some well known ones are IP (Indian pharmacopoeia), BP (British pharmacopoeia), USP (United States Pharmacopoeia) Next, I want to talk about Formulary, its supervised in a land by set of pharmacists. Very useful information like drug use indications, drug dose, dosage form, cautions, contraindications, side effects and much more is covered in this. Description of drug class precedes the discussion of drug itself. Some well known examples are British National Formulary (BNF), National Formulary of India (NFI). With this chit chat about Official Drug Compendia, next topic to be discussed is Non Official Drug Compendia, surely to be in next episode...I will be call it for the day, Wishing you all a great , safe weekend!! For all the updates and latest episodes of my podcast, please visit www.ispharmacologydifficult.com where you can also sign up for a free monthly newsletter of mine. It actually contains lot of updates about the medical sciences, drug information and my podcast updates also. You can follow me on different social media handles like twitter, insta, facebook and linkedin. They all are with same name "IS PHARMACOLOGY DIFFICULT". If you are listening for the first time, do follow me here, whatever platform you are consuming this episode, stay tuned, do rate and review on ITunes, Apple podcasts, stay safe, stay happy, stay enlightened, Thank you!!

Welcome all to IS PHARMACOLOGY DIFFICULT Podcast! I am Dr Radhika Vijay.Does your textbook cover all the minute details, I mean all, everything like trade names, drug information, purity, chemical, physical characteristics, etc? Well, if not, in today's episode you will get the knowledge of drug information sources, especially official ones.The collective term used for drug literature is "Drug Compendia". When I say its official, it means that government supervises it. The two main Official Drug Compendia are Pharmacopeia and Formulary.Pharmacopoeia is supervised in a country by a set of chosen physicians. It covers drug details like chemical structure and properties, physical properties and molecular weight, assay techniques, drug preservation and storage methods, etc. Such a kind of information is very useful for drug regulators and drug manufacturers. Its hardly of any use to the clinical practitioners. Some well known ones are IP (Indian pharmacopoeia), BP (British pharmacopoeia), USP (United States Pharmacopoeia)Next, I want to talk about Formulary, its supervised in a land by set of pharmacists. Very useful information like drug use indications, drug dose, dosage form, cautions, contraindications, side effects and much more is covered in this. Description of drug class precedes the discussion of drug itself. Some well known examples are British National Formulary (BNF), National Formulary of India (NFI). With this chit chat about Official Drug Compendia, next topic to be discussed is Non Official Drug Compendia, surely to be in next episode...I will be call it for the day, Wishing you all a great , safe weekend!! For all the updates and latest episodes of my podcast, please visit www.ispharmacologydifficult.com where you can also sign up for a free monthly newsletter of mine. It actually contains lot of updates about the medical sciences, drug information and my podcast updates also. You can follow me on different social media handles like twitter, insta, facebook and linkedin. They all are with same name "IS PHARMACOLOGY DIFFICULT". If you are listening for the first time, do follow me here, whatever platform you are consuming this episode, stay tuned, do rate and review on ITunes, Apple podcasts, stay safe, stay happy, stay enlightened, Thank you!!

Joel Hennenfent, Pharm.D., M.B.A., BCPS, FASHP, sits down with Ali McBride, Pharm.D., M.S., BCPS, to discuss biosimilar formulary implementation/integration and reimbursement challenges.To learn more about Formulary Management Strategies visit www.formularytoolkit.orgThe information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

White bagging is a major patient safety issue driven by payers within hospitals today.  Candy Tsourounis, Pharm.D., FCSHP sits down with Joel Hennenfent, Pharm.D., MBA, BCPS, FASHP to discuss those safety issues and best practices on how to prevent white bagging to keep our patients safe.To learn more about Formulary Management Strategies visit www.formularytoolkit.org.The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

Have you been dying to know how the prescription drug formulary works? Or do you want to avoid going to pick up a prescription only to learn it isn't covered or expensive? Listen in as we run through the formulary and review how to confirm coverage and cost when choosing a health insurance plan.

Joel Hennenfent, Pharm.D., M.B.A., BCPS, FASHP, Chief Pharmacy Officer & Associate Administrator for Laboratory and Medical Imaging, sits down with Karl Gumpper, MSMI, RPh, BCPS, CPHIMS, FASHP, Pharmacy Informatics Manager at Boston Children’s Hospital, to discuss aspects of integrating biosimilars into pharmacy IT systems, a challenge that every hospital is working through.To learn more about Formulary Management Strategies visit www.formularytoolkit.org The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.

The biosimilars represent a significant value improvement opportunity for health system formularies nationwide. This podcast will review the biosimilar challenges facing health systems and strategies that can be used to increase biosimilar adoption. The information presented during the podcast reflects solely the opinions of the presenter.  The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician. 

Situation Situation Pantoprazole 80 mg in NS 100 mL drip is being used for GI Bleeds due to ulcers Problem: Evidence not being clear on Continue reading The post Episode 25: Pantoprazole Continuous infusion vs Intermittent Bolus Formulary Nugget by Oscar Santalo appeared first on The Pharm So Hard Podcast.

Pharmacy costs have risen over the years and have gained the attention of regulators as well as health plans, employers, and consumers.  The idea of cost transparency and rebates have also generated a lot of discussion more recently.  More than 60 PBMs administer prescription drug plans for more than 270 million Americans.  Our guest is JC Scott, President of the Pharmaceutical Care Management Association (PCMA), which is a national association representing America’s pharmacy benefit managers, or PBMs.  Today, JC will explain why drug costs are high and the roles PBMs play in helping to contain costs.   Show notes:  Book: March by John Lewis; Podcast: The Pharmacy Benefit by the PCMA

Carm Huntress, CEO of RxRevu, joins hosts, Gary Austin and Pooja Babbrah to discuss price transparency. Gary asks Pooja to start the discussion with a primer for price transparency. Pooja states that the topic itself is quite complex and, unfortunately, not very transparent. When receiving a prescription from your doctor, you never really think to ask if you should go to a different pharmacy or if there are coupons available for the medication. You simply pick up the prescription and pay the price that is due. Additionally, since the price of medications are going up, many patients do not pick up prescriptions because they are too expensive. Patients cannot afford to pay for them. Pooja explains that when we think about price transparency, it is all about being transparent with the consumer, letting them know what prescriptions and procedures are actually going to cost them out-of-pocket.Gary then asks Carm to briefly go over RxRevu and to give some opening comments about price transparency. Carm shares that RxRevu is a Denver based company focused on price transparency around drugs. The company helps providers at the point of care make cost-effective decisions by providing a large amount of information. Carm says on a monthly basis, RxRevu is helping millions of patients around affordability issues with their prescription drugs.There is a recent CMS ruling requiring hospitals and payers to post their charges online. Gary asks Carm what all of this means for consumers. Carm says the big idea of this ruling is directionally right. Healthcare is really the only industry where consumers don't know the price of products and services before they buy them. Carm explains that the problem with price transparency is that there's so much complexity in actually pricing medications and procedures, especially since negotiations are affecting these prices. Pooja says this ruling was an important step forward. There's a list of 300 items hospitals and payers are required to give pricing on. She notes that it may not be easy for them to offer this information and the timing for when they actually provide a complete list may be far into the future. Gary points out that price transparency sounds like a good thing for consumers, but what about the physicians? Gary asks Carm if the availability of this information will really change physicians' prescribing and referral habits. Carm explains that price transparency thoughtfully puts the right type of information into workflow, including what the patient will pay at their preferred pharmacy, types of lower cost therapeutic alternatives and insurance coverage. Carm states early findings show that one in every five doctors who are presented with this information make a cost-dynamic change.Prescription price transparency is moving along faster than medical procedure transparency, is that a fair observation and if so, why? Carm agrees with Gary and believes this is the case because the need for price transparency in pharmacy has been driven harder given the longevity of the idea. He says the claims system and the engines that we talk to in terms of getting the data out are a little less complex than on the medical side. The PBMs and the systems behind the PBMs were more ready to do real time benefit and that's why it came to market and matured faster. Gary asks Pooja what's going to be the tipping point for price transparency across the industry. Is there some event or some thing that will be a tipping point as we look out a year? Pooja thinks that from the PBM to the physician standpoint, we're almost there, but in order to progress further, we need to incorporate the consumer side. Doctors can't be price shopping for consumers all the time, so that's where we bring in the second piece of consumer-facing price transparency.RxRevu is growing exponentially. What is your company doing better, faster, or cheaper than the next guy with price transparency? Carm explains price transparency is the company's singular focus, which allows them to execute at a high level. RxRevu works alongside clinicians to finetune those transactions to make sure they go through clean and with the best experience possible. Secondly, Carm notes the company is a startup. There is no legacy business or bureaucracy in their organization. There's a real mission in delivering more value through better prescribing decisions. Lastly, Carm states that RxRevu is a startup. They have taken venture money, but also have several health systems as major investors. This has allowed the company to have a much more intimate relationships with providers at the point of care. Carm believes it has allowed them to uncover things others have not. Why haven't digital companies like Amazon or Yelp entered this space? Or have they and just failed? Carm says more than $10 billion dollars have been invested in digital healthcare over the past 10 years and we're really not seeing any outcomes. He believes this is happening due to the wide-spread assumption that the consumer is always the answer. Carm suggests focusing dollars and efforts on improving physician decision making instead. To conclude the discussion, Gary asks Carm to explain what he would say to a payer CEO about price transparency. Carm stresses this is the number one thing you can do. Bringing transparency is one of the first and most effective things you can do to help physicians understand there are lower-cost options. It's informed autonomy for the doctors. They still have the decision power, but you want those decisions to be informed by a high level of information and a narrow set of options. 

On this episode Wayne Setser and Andrew Bartram join me for a round table discussion of various darkroom topics such as: Right to Left or Left to Right, which way to do you process Split Grade printing Lith Printing Caffenol This podcast was a lot of fun to record. Wayne and Andrew have a wealth of knowledge to offer and it was an honor to participate in this event. Look for more Round Table podcast in the near future. Social Media Links Andrew: Instagram - WarboysSnapper - https://www.instagram.com/warboyssnapper/ Flickr - WarboysSnapper - https://www.flickr.com/photos/warboyssnapper FaceBook - https://www.facebook.com/andrew.bartram.35 Wayne: Instagram - wayne_setser - https://www.instagram.com/wayne_setser/ Flickr - wsetser - https://www.flickr.com/photos/wsetser FaceBook - https://www.facebook.com/wsetserBook - John: Instagram - jwgregphoto- https://www.instagram.com/jwgreg60/ Flickr - jwgreg - https://www.flickr.com/photos/jwgreg/ FaceBook - https://www.facebook.com/jwgregphoto email - lightdark@mediagg.com Links referenced in podcast: Moersch Lith Chemicals - https://www.freestylephoto.biz/category/14-Chemicals/Alternative-Process-Chemicals?mfg%5B%5D=245 FomaTone Paper - https://www.freestylephoto.biz/search?q=FomaTone Tim Rudman - http://timrudman.com/ Elsa Dorfman - https://bsidefilm.com/ Photographers Formulary - https://www.bhphotovideo.com/c/buy/Shop-by-Brand-Photographers%27-Formulary/ci/4/phd/4291277664/N/4294255798

This week on Dev Party we’re trying a new-to-us developer! Well… that’s not quite true. You’ll see.It was Vania’s idea to give Pyro a try, so we both picked up PMK Pyro by Photographer’s Formulary. And well… you’ll see.Here on Dev Party, we are certainly used to and even welcoming of failures. They can lead to more knowledge and better days. And this failure is no different. It was just weird and unexpected. Again, you’ll see.This was the first time we ever tried this developer. You’ll hear us reading from the instructions, talking a bit about what Pyro is, and witness our first experiences with the developers. Basically.The important thing is that we both liked the results.And speaking of results, here are some scans…  We also hear from Aloy Anderson and Jennifer Froula Webber about their thoughts and tips for shooting Fuzzy Pürrito!

In response to customer requests, we’ve built some new tools for formulary management. You can preview these tools at: Recent Generic Drug Launches Upcoming 180-Day Patent Challenge Exclusivity Expirations Anticipate… The post Customer Success: Formulary Management appeared first on DrugPatentWatch - Make Better Decisions.

Hey Medicare Nation! www.TheMedicareNation.com Medicare has taken many steps to assist you during the COVID-19 crisis. Coronavirus tests Medicare Part B (Medical Insurance) covers a test to see if you have coronavirus (officially called COVID-19). This test is covered when your doctor or other health care provider orders the test. I spoke about testing for COVID-19 in the previous episode, dated April 1, 2020. Listen to episode 101 to learn more about COVID-19 Testing. Your costs in Original Medicare for COVID-19 Testing. You pay nothing for this test. NADA! This includes the newly available COVID-19 “Antibody” test, which determines if you have antibodies in your blood, that were created to recognize the COVID-19 Virus in your body. Hospitalization Medicare covers All medically necessary hospitalizations. This includes if you're diagnosed with COVID-19 and might have been discharged from the hospital after an inpatient stay, but……. instead you need to stay in the hospital under quarantine.   Your costs in Original Medicare ZERO!   3     VACCINE FOR COVID-19 At this time, there's no vaccine for COVID-19.  However, If and when one becomes available, it will be covered by all  MEDICARE Prescription Drug plans -  Which is Part D of Medicare.   TELEHEALTH  SERVICES During the National Emergency for COVID-19, you will be able to receive a specific set of services through telehealth These services include: Evaluation and management visits (common office visits), mental health counseling and preventive health screenings  without a copayment if you have Original Medicare.  Your costs in Original Medicare  $0  Co-Pay if you have Original Medicare. You can use your smart phone or computer to access Telehealth services. 5.    Virtual check-ins virtual check-ins (also called “brief communication technology-based services”) with your doctors and certain other practitioners. What is it ? Virtual check-ins allow you to talk to your doctor or certain other practitioners, like nurse practitioners or physician assistants, using a device like your phone, integrated audio/video system on your laptop or computer, or captured video image without going to the doctor’s office. Your doctor or other practitioner can respond to you using: Phone Audio/visit Secure text messages Email Use of a patient portal   Virtual Check-Ins can be used for treatment for the Coronavirus from ANYWHERE……including places of residences….HOMES. Nursing Homes, AND Assisted Living Facilities.       Things to know You must talk to your doctor or other practitioner to start these types of visits. The communication must not be related to a medical visit within the past 7 days and must not lead to the medical visit within the next 24 hours (or the soonest appointment available). You must verbally consent to the virtual check-in, and your consent must be documented in your medical record. Since January 1, 2020 your doctor may obtain a single consent for a year’s worth of these services.        Your costs in Original Medicare      Normally, you would pay for “Virtual Visits” under Part B of Medicare.      During the National Emergency, your co-insurance and deductible will be waived, and you will have “No Co-insurance, or deductible” for Virtual Visits for COVID-19 services.   Certain Skilled Nursing Facility Care requirements have been waived during the National Emergency for COVID-19. During the COVID-19 Pandemic, some people may be able to get renewed SNF coverage without first having to start a new benefit period.  Original Medicare covers up to “100 consecutive days” in a Skilled Nursing Facility.” For each benefit stay. During the National Emergency for COVID-19, your Doctor may request an extension of days for your benefit period.   If you’re not able to be in your home during the COVID-19 pandemic or are otherwise affected by the pandemic, you can get SNF care without a qualifying hospital stay.   if you have a Medicare Advantage Plan, you have access to these same benefits. Medicare allows these plans to waive cost-sharing for COVID-19 lab tests. Many plans offer additional telehealth benefits beyond the ones described above and many plans have waived Hospital co-pays during the pandemic. Check with your plan about your coverage and costs for ALL services covered for COVID-19. Review your Summary of Benefit Booklet for 2020 from your Medicare Advantage Plan Carrier. Don’t have one……… Go to the plan’s website to download a digital copy. OR…… Call the Customer Service number on the back of your Identification card and ask them to mail you a “Formulary” for your Specific plan.     Preparing for healthcare needs   Be sure you have over-the-counter medicines and medical supplies like tissues….cough drops…. Tylenol…etc.  to treat fever and other symptoms.   Most people will be able to recover from COVID-19 at home.   Have enough household items and groceries on hand…..Soup, Macaroni and Cheese, Bread for Toast…. Whatever it is you will eat & drink when you’re sick….so that you'll be prepared to stay at home for a period of time.   Check out the following websites for updates on COVID-19   Centers for Disease and Control - CDC.gov …..  has the latest public health and safety information from the CDC and for the medical and health provider community on COVID-19.   USA.gov -  has the latest information about what the U.S. Government is doing in response to COVID-19.   CoronaVirus.gov - is the source for the latest information about COVID-19 prevention, symptoms, and answers to frequent questions.   Visit your State Department of Health for local COVID-19 Information about YOUR State.   You can search on Google for your State’s Health Dept. by typing in ……… NY State Health Depart……… CA State Health Dept……..Florida State Health Depart……    Visit my website for a LIST of EVERY State Health Department’s Phone Number…… By going to www.TheMedicareNation.com/COVID19     Many of you are turning 65 and have no idea what to do to enroll in Medicare or what Plan to enroll in. I invite you to contact me….. so that I can assist you with all this. Send me your question to Support@TheMedicareNation.com   I answer ALL emails myself! No Assistants, NO Virtual Assistants….. I do! I will answer your question in one paragraph. If I cannot, I will let you know how to contact me if you wish to reach out to me for a consultation. Until next time……. Practice Social Distancing…..Do things to Make you Happy……. AND Stay Healthy!! Thank you for listening to Medicare Nation! If you are part of my “Sandwich Generation,” Share this show with your parents and/or grandparents. They have many questions about Medicare and this show will answer them! Buy them a “Smart Phone,” and introduce them to Medicare Nation! If you are a Baby Boomer, share Medicare Nation with other “Baby Boomers.” I want to educate as many of you as I can about Medicare! I certainly can use  your help in putting the word out! If you have any questions, send them to Support@TheMedicareNation.com If I can answer it in one email - I will personally answer you! If your question requires research or additional contact with you, I do offer consulting if you would like me to assist you in that manner. Want to hear a topic on Medicare Nation? A special guest? Let me know and I'll do my best to get them on the show! Thanks again for listening!   The information on this podcast and/or website is not a substitute for examination, diagnosis, and medical care provided by a licensed and qualified health professional, which neither I nor anyone else associated with Medicare Nation LLC is not! Please consult with your physician before undertaking any form of medical treatment and/or adopting any exercise program or dietary guidelines. If you think you may have a medical emergency, call your physician and/or 911 immediately. Medicare Nation LLC reserves the right to add, remove or edit content on this page at its’ sole discretion.

Definitions Formulary medication – A determination that the medication is “appropriate for routine use” in select patient populations Per 2008 ASHP Guidelines on the Pharmacy Continue reading The post Episode 10. Formulary Management with Oscar Santalo appeared first on The Pharm So Hard Podcast.

Digital health solutions create new ways for people to manage their health from their phones and computers, but with hundreds of thousands of digital solutions already on the market, it can be hard to know what works and what doesn’t. Dr. Zachary Goodman, MD sits down with us to talk about how we’re helping sift through the ever-expanding landscape of digital health with our first-of-its-kind Digital Health Formulary. As Director of Clinical Innovation, Dr. Goodman shares how Express Scripts is making digital health click while embracing the technology that’s taking us into the future. Please note, the views and opinions expressed in this podcast are those of the interviewees and do not necessarily reflect the views of Cigna, Express Scripts, or their subsidiary companies.

How to attend these webinars live and ask questions. Join us for our monthly webinars on New York and New Jersey workers’ compensation law. Register here: Register Archive of prior presentations is here. Schedules and Information. Handout materials are provided in advance of each session. The webinar courses follow the "life cycle" of a claim and correspond to chapters in the Workers' Compensation Handbooks offered by the Firm. Upcoming Webinars Detailed syllabus and schedule available here. Disclaimer: This webinar is not legal advice! The materials presented by this webinar/podcast and any affiliated website are for informational purposes only and are not offered as legal advice as to any particular matter. No viewer/listener/reader should act on the basis of these materials without seeking appropriate professional advice as to the particular facts and applicable law involved. The materials are not represented to be correct, complete, or up-to-date. Opinions presented by this video/podcast are the opinions of the author. Neither the use of this web site nor the transfer of information to or from this web site shall create or constitute an attorney-client relationship between Greg Lois, the presenter in the video/podcast, or LOIS LAW FIRM LLC and any person. You should not send any confidential information to this web site until after you have entered into a written agreement for the performance of legal services.

Should hospitals stock Andexxa?

Rene Thomas Folse, JD, Ph.D. is the host for this edition which reports on the following news stories. CA AG Belatedly Files Limited Opioid Litigation, Another Opioid Manufacturer Pleads Guilty to Kickbacks, L.A. Dentist Sentenced for $3.8M Fraud Scheme, So. Cal. Contractors Cited for $600K Wage Theft, VA Promotes Telehealth, and E-Record Systems, Ohio BWC Drops Oxycontin from Formulary, HHS Publishes Pain Management Best Practices, Mild Brain Injury Can Cause Lasting Effects, SCIF Launches Real-Time UR Approval, Quest Diagnostics Records Hacked.

The boys talk about gum bichromate printing where a color image is created from three black and white photographs, each of which was taken using a different colored filter over the lens. There is an Instructables page on this process: (https://www.instructables.com/id/Tri-color-gum-bichromate-prints-from-digital-image/). B&H sells a kit from Photographer’s Formulary that supplies this process (https://www.bhphotovideo.com/c/product/123480-REG/Photographers_Formulary_07_0100_Classical_Gum_Printing_Kit.html). Graham can’t remember Brendan Berry Photo’s Instagram name. He’s the guy who created the large format photographs in the skyscraper in New York. It’s incredibly compelling work. (https://www.instagram.com/brendanbarryphoto/) Ultrafine Online have a line of paper that is panchromatic. (http://www.ultrafineonline.com/ilpapaforpic.html) If you are in the Victoria BC area, visit the Butchart Gardens. (https://www.butchartgardens.com/)

Drug patent expiration doesn’t always mean generics enter the market right away. Many factors affect generic drug launches and drug formulary changes. The post Formulary Management and LCM Patent Strategies: A Complex Interaction appeared first on DrugPatentWatch - Make Better Decisions.

Canada has a universal medicare system, but there is a big gap when it comes to ensuring people can afford the medication they need. Currently, one in four households can’t afford their prescription drugs. The Advisory Council on the Implementation of National Pharmacare has just issued an interim report to the federal government. Melanie Benard is with the Canadian Health Coalition. We asked her for her reaction to the report.

Canada has a universal medicare system, but there is a big gap when it comes to ensuring people can afford the medication they need. Currently, one in four households can’t afford their prescription drugs. The Advisory Council on the Implementation of National Pharmacare has just issued an interim report to the federal government. Melanie Benard is with the Canadian Health Coalition. We asked her for her reaction to the report.

THIS EPISODE IS SPONSORED BY: AROMATICS INTERNATIONALWe provide 100% pure essential oils and natural aromatherapy products, sourced in-house, from small-scale producers located in over 60 different countries. Find out more: https://www.aromatics.com/Topics covered in this episodeWhat is a Neuro-degenerative Disease?How a healthy nervous system is supposed to functionHow St. Johns Wort, Licorice Root and Turmeric can support nervous system healthSpecific advice and information about Parkinson’s Disease and Alzheimer’sThe relationship between blood sugar, Diabetes and Alzheimer’s / DimentiaHow Turmeric and Cinnamon can support our mental healthTwo great herbal recipes (Herbal Chai Tea and Herbal Energy Balls) for supporting our brainsPreventative tips to help maintain a healthy nervous system and brainABOUT Holly BellebuonoHolly Bellebuono is an American herbalist, author and speaker on natural health, women’s empowerment, herbal medicine, and visionary thinking. She directs The Bellebuono School of Herbal Medicine on Martha’s Vineyard, providing training and certification courses, and her books include the award-winning documentary Women Healers of the World, The Authentic Herbal Healer, The Essential Herbal for Natural Health, An Herbalist’s Guide to Formulary, and Goal-Setting. As an entrepreneur, Holly is a 2-time Business Owner of the Year Award winner, and her work is featured in Parabola, Sage Woman, Juno, and Taproot magazines. She speaks and leads workshops and retreats internationally.WHERE TO FIND Holly BellebuonoWebsite: https://www.hollybellebuono.com/Facebook: https://www.facebook.com/holly.bellebuonoInstagram: https://www.instagram.com/hollybellebuono/Buy Holly’s Books on Amazon: https://amzn.to/2ETbZeBThis Podcast is brought to you by AromaCulture Magazine - AromaCulture Magazine is filled with educational articles, case studies and recipes written by practicing herbalists and qualified aromatherapists. Our February issue centers around the topic of mental health. You can find it at https://www.aromaculture.com/shop/february2019.Disclaimer: The information presented in this podcast is for educational purposes only, and is not meant to replace professional medical advice. Please consult your doctor if you are in need of medical care, and before making any changes to your health routine.

As costs continue to rise and reimbursements decline, hospitals and health systems are looking for new ways to control expenses without affecting the quality of care. Discover the key steps and initiatives to start successfully standardizing a surgical pack program. Participants will obtain: -The steps to implement, sustain, manage and improve your standardization efforts -How to help clinicians work more efficiently and reduce variation   -The importance of data science in standardization   Sponsored by Cardinal Health   For more information, visit CardinalHealth.com/PresourceServices  

Pharmaceutical formulary managers have a pressing need to manage their formulary budgets. Anticipating when drugs will face loss-of-exclusivity — when their key patents will expire — is an essential first-step… The post Pharmaceutical Formulary Management: Anticipating generic entry, identifying first generic entrants, and projecting drug price drops appeared first on DrugPatentWatch - Make Better Decisions.

Inside EMS: Is it time to pull epinephrine from the EMS formulary? by EMS1 Podcasts

Topics: Pharmacy Benefit Manager Self-Funded Health Plan Misaligned Incentives Rebates Formulary Waste Formulary Design Specialty Drugs Clinical Programs Performance Guarantees In this episode, Michael introduces you to Mindi Fynke, President and CEO of Employee Health Insurance Management (EHiM). Join us as we discuss EHiM’s unique service-oriented PBM model and how they can effectively lower an employer-sponsored health plan’s drug spend. Here’s a glance at what we discuss in this episode: Mindi Fynke’s clinical experience and why she founded EHiM   How rebates from drug manufacturers are intended to move market share and the act of taking rebates from drug manufacturers can be a misaligned incentive and contribute to increased healthcare costs How EHiM seek to address pharmacy waste in an employer’s sponsored health plan’s drug spend with custom formulary design and clinical programs for each client’s unique demographics and claims The conflict of interest that may exist when PBM’s own their own specialty pharmacies EHIM’s book of business Specialty Trend is 6% relative to National Specialty Trend of 18% How EHiM implements a unique solution of clinical interventions and negotiations with drug manufacturers to help employers manage their specialty pharmacy trend well below the national average The difference between a traditional PBM’s customer service and EHiM’s patient advocacy model How EHiM competes in the market without receiving or offering drug manufacturer rebates, driving savings of 20% -30% in overall drug spend Examples of misaligned incentives in formulary design that can be costly to the employer and how EHiM can customize many components in Pharmacy Benefit Administration (Network, Formulary, Plan Design, Clinical Programs) to “move market share” towards lower cost alternatives EHiM’s transparent fee structure options EHiM’s ability to provide performance guarantees based on actual employer net spend vs “discount guarantees” EHiM’s new and exciting technology capabilities with state of the art adjudication system The difference between partnering with a smaller pharmacy benefit manager compared to a larger PBM EHiM’s website and contact information: ehimrx.com, mindi@ehimrx.com

Topics covered in this episode The inspiration behind her book, An Herbalist's Guide to Formulary The historic and time-tested methods of herbal formulation still in use Why the "magic bullet" approach is neither effective or realistic Holly's 4-tier guide to herbal formulation Specific herbs for each tier Sleep and it’s relation to emotional health Aromatherapy and the 4-tier system Basic safety and dosage guidelines for herbal formulas About HOLLY Holly Bellebuono is an American herbalist, author and speaker on natural health, women’s empowerment, herbal medicine, and visionary thinking. She directs The Bellebuono School of Herbal Medicine on Martha’s Vineyard, providing training and certification courses, and her books include the award-winning documentary Women Healers of the World, The Authentic Herbal Healer, The Essential Herbal for Natural Health, An Herbalist’s Guide to Formulary, and Goal-Setting. As an entrepreneur, Holly is a 2-time Business Owner of the Year Award winner, and her work is featured in Parabola, Sage Woman, Juno, and Taproot magazines. She speaks and leads workshops and retreats internationally. Where to find HOLLY Website: https://www.hollybellebuono.com/ Facebook: https://www.facebook.com/holly.bellebuono Instagram: https://www.instagram.com/hollybellebuono/ Disclaimer: The information presented in this podcast is for educational purposes only, and is not meant to replace professional medical advice. Please consult your doctor if you are in need of medical care, and before making any changes to your health routine.

The Spiritual Nature of Animals with Karlene Stange, DVMAs a child, Karlene Stange, DVM, wanted to be an “animal doctor” before she knew the word “veterinarian.” Today she incorporates acupuncture, traditional Chinese herbal medicine, and nutritional therapy into her Rocky Mountain practice. She often speaks at conferences and lives in Durango, Colorado. http://www.animasanimals.comAn Herbalist’s Guide to Formulary with Holly BellebuonoHolly Bellebuono (Massachusetts) has been a community herbalist, apothecary director, and teacher for over two decades. She uses her inspiring lectures, books, curriculum, retreats, and workshops to empower people to think creatively and explore healing and success. https://www.hollybellebuono.com

If you’re in the Sandwich Generation, more likely than not, your parents are on medicines.  Maybe just one prescription, if you’re lucky, or maybe enough to fill up an entire closet.  Either way, prescriptions are a serious topic and we need to be advocates for our parents.  The more we know about how to handle their meds, the more we can protect our parents.  In this episode, Janice – a pharmacist for over 30 years, talks about: -Refills: When to refill, how to refill. -Generics:  Who orders them. -Pill containers: Best ways to organize and a little known fact about something pharmacies will do for their customers. -Formulary changes: When you’re denied, what do you do?  -Medicine lists: How to organize, what to do with a list and why a paper list might be better than a digital one. Take a look at the list I kept for my dad that saved me from going crazy!   And much, much more. 

In the latest Managed Care Cast, Patricia Salber, MD, MBA, of The Doctor Weighs In, speaks with Kai Yeung, PharmD, PhD, about his winning research paper on creating a value-based formulary.

Today I answer an email that came in about what to do and say when you are wanting to change RN jobs while you are in NP school.  I had this same issue happen to me and I give my opinion on what to do.  Ohio has changed the formulary to include NPs being able […] The post Episode 022 – RN Job Searches While in NP School, Ohio Formulary, and My Take on Age of Consent first appeared on The NP Dude.

Today is a hodgepodge of info that has been rattling around in my head and I take the opportunity to let it fall out!  I give my perspective as an attorney and FNP as to how and negotiate payment structure when you are the first APRN in a group or facility.  I also provide my […] The post Episode 009 – Payment Structure, Ohio HB 216 Changes, and the new CARA law first appeared on The NP Dude.

Android - Free - requires NHS authentication iOS - Free - requires NHS authentication

Researchers from Tufts Medical Center analyzed findings from 26 studies to determine how drug exclusion policies affect patients and healthcare costs. They found that in most cases, exclusion policies work. Dr. Patricia Salber, of The Doctor Weighs In, interviewed the lead author, Dr. James Chambers, to discuss his findings. Read the full study: http://www.ajmc.com/journals/issue/2016/2016-vol22-n8/the-impact-of-formulary-drug-exclusion-policies-on-patients-and-healthcare-costs

Explanation of the tiers within the Yale Health Drug List, how drugs are placed on the tiers and why they sometimes move .

Celeste Rayne Heldstab (Monroe, LA) has over twenty-five years of experience creating oils and incense for companies and individuals. Since 2000, she has taught many workshops on how to utilize essential oils in magical applications, along with tarot reading and incense making. She follows an eclectic spiritual path that incorporates Native American beliefs and voodoo, and manages an online store that sells incense, oils, and other products.

Celeste Rayne Heldstab (Monroe, LA) has over twenty-five years of experience creating oils and incense for companies and individuals. Since 2000, she has taught many workshops on how to utilize essential oils in magical applications, along with tarot reading and incense making. She follows an eclectic spiritual path that incorporates Native American beliefs and voodoo, and manages an online store that sells incense, oils, and other products.